BIRC7 antibody (Middle Region)
Quick Overview for BIRC7 antibody (Middle Region) (ABIN926876)
Target
See all BIRC7 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- Middle Region
-
Purification
- Purified
-
Immunogen
- BIRC7 antibody was raised in rabbit using the middle region of BIRC7 as the immunogen
-
-
-
-
Application Notes
-
WB: 0.2-1 µg/mL
Optimal conditions should be determined by the investigator. -
Comment
-
BIRC7 Blocking Peptide, , is also available for use as a blocking control in assays to test for specificity of this BIRC7 antibody
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- Lot specific
-
Buffer
- Lyophilized powder. Add 50 µL of distilled water. Final antibody concentration is 1 mg/mL in PBS buffer.
-
Handling Advice
- Avoid repeated freeze/thaw cycles.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store at 4 °C, following reconstitution, aliquot and store at -20 °C.
-
-
- BIRC7 (Baculoviral IAP Repeat-Containing 7 (BIRC7))
-
Alternative Name
- BIRC7
-
Background
- BIRC7 protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine. Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2. This activation depends on TAB1 and NR2C2/TAK1. In vitro, inhibits caspase-3 and proteolytic activation of pro-caspase-9. Isoform 1 blocks staurosporine-induced apoptosis. Isoform 2 blocks etoposide-induced apoptosis. Synonyms: Polyclonal BIRC7 antibody, Anti-BIRC7 antibody, baculoviral IAP repeat-containing 7, livin antibody, KIAP antibody, LIVIN antibody, ML-IAP antibody, MLIAP antibody, RNF50 antibody.
Target
-